SCHEMBL1019998

SCHEMBL1019998

O=C(c1ccccc1)N1CCN(Cc2ccccc2)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.94
ALDH1A1 P00352 1/20 0.94
MEN1 O00255 4/20 0.85
KMT2A Q03164 4/20 0.85
LMNA P02545 3/20 0.85
MAPK1 P28482 2/20 0.85
SMN1; SMN2 Q16637 2/20 0.85
TSHR P16473 1/20 0.85
L3MBTL1 Q9Y468 1/20 0.85
CHRM2 P08172 1/20 0.75
CHRM3 P20309 1/20 0.75
SIGMAR1 Q99720 1/20 0.74
CA12 O43570 1/20 0.72
CA1 P00915 1/20 0.72
CA2 P00918 1/20 0.72
CA7 P43166 1/20 0.72
CA9 Q16790 1/20 0.72
CA14 Q9ULX7 1/20 0.72
KCNH2 Q12809 1/20 0.71
NPC1 O15118 1/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9645824 1.00 KDM4E (0.94) KDM4EALDH1A1MEN1KMT2ALMNA
SCHEMBL13149349 0.91 KDM4E (0.78) KDM4EALDH1A1MEN1KMT2ALMNA
SCHEMBL4486386 0.91 KDM4E (0.78) KDM4EALDH1A1MEN1KMT2ALMNA
SCHEMBL4515670 0.89 KDM4E (0.76) KDM4EALDH1A1MEN1KMT2ALMNA
SCHEMBL4516322 0.89 KDM4E (0.76) KDM4EALDH1A1MEN1KMT2ALMNA
SCHEMBL25041158 0.89 KDM4E (0.76) KDM4EALDH1A1MEN1KMT2ALMNA
SCHEMBL20121634 0.89 KDM4E (0.76) KDM4EALDH1A1MEN1KMT2ALMNA
SCHEMBL7474168 0.89 KDM4E (0.76) KDM4EALDH1A1MEN1KMT2ALMNA
SCHEMBL17696082 0.89 KDM4E (0.76) KDM4EALDH1A1MEN1KMT2ALMNA
SCHEMBL12452433 0.89 ALDH1A1 (0.76) KDM4EALDH1A1MEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250066320-A1 Active Ingredients with Sialagogue and Tingling/Fizzy Effect, and Preparations Containing Same SYMRISE AG (DE) 2025-02-27 US claimed
US-20250066320-A1 Active Ingredients with Sialagogue and Tingling/Fizzy Effect, and Preparations Containing Same SYMRISE AG (DE) 2025-02-27 US disclosed
EP-4452941-A1 ACTIVE INGREDIENTS WITH SIALAGOGUE AND TINGLING/FIZZY EFFECT, AND PREPARATIONS CONTAINING SAME Symrise AG (DE) 2024-10-30 EP disclosed
WO-2023117119-A1 ACTIVE INGREDIENTS WITH SIALAGOGUE AND TINGLING/FIZZY EFFECT, AND PREPARATIONS CONTAINING SAME SYMRISE AG (DE) 2023-06-29 WO disclosed
WO-2023117119-A1 ACTIVE INGREDIENTS WITH SIALAGOGUE AND TINGLING/FIZZY EFFECT, AND PREPARATIONS CONTAINING SAME SYMRISE AG (DE) 2023-06-29 WO disclosed
US-20230050965-A1 SSTR5 ANTAGONISTS KALLYOPE, INC. 2023-02-16 US disclosed
US-11345885-B2 Agent for inducing callus and method for inducing callus RIKEN (JP) 2022-05-31 US disclosed
EP-3153014-B1 AGENT FOR INDUCING PLANT CALLUS AND METHOD FOR INDUCING PLANT CALLUS RIKEN (JP) 2020-12-30 EP disclosed
US-20200255797-A1 AGENT FOR INDUCING CALLUS AND METHOD FOR INDUCING CALLUS RIKEN (JP) 2020-08-13 US disclosed
US-10676711-B2 Agent for inducing callus and method for inducing callus RIKEN (JP) 2020-06-09 US disclosed
US-20090203673-A1 4-HETEROCYCLOALKYLPYRI(MI)DINES, PROCESS FOR THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-08-13 US disclosed
WO-2009024550-A1 N-BENZYL, N' -ARYLCARBONYLPIPERAZINE DERIVATIVES AS LXR MODULATORS N.V. ORGANON (NL) 2009-02-26 WO disclosed
WO-2008003766-A2 4-HETER0CYCL0ALKYLPYRI(MI)DINES, PROCESS FOR THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-01-10 WO disclosed
US-20070010529-A1 Nitrogenous heterocyclic compounds and medical use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2007-01-11 US disclosed
US-20070010529-A1 Nitrogenous heterocyclic compounds and medical use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2007-01-11 US disclosed
EP-1229025-A1 NOVEL QUINAZOLINE DERIVATIVES Japan Energy Corporation (JP) 2002-08-07 EP disclosed
US-6235731-B1 REDUCING BLOOD LIPIDS, SUGARS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2001-05-22 US disclosed
EP-0915888-A1 FUSED IMIDAZOPYRIDINE DERIVATIVES AS ANTIHYPERLIPIDEMIC AGENTS Takeda Chemical Industries, Ltd. (JP) 1999-05-19 EP disclosed
WO-1997040051-A1 FUSED IMIDAZOPYRIDINE DERIVATIVES AS ANTIHYPERLIPIDEMIC AGENTS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1997-10-30 WO disclosed
US-4663641-A LEUCO DYES; DECOLORIZING AGENTS, PIPERAZINE COMPOUND; AMIDES AND TERTIARY AMINES RICOH COMPANY, LTD. (JP) 1987-05-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010529-A1 Nitrogenous heterocyclic compounds and medical use thereof MAPK1, NOS1, NOS2 KDM4E 4309/4885ALDH1A1 1694/4885MEN1 2309/4885
US-20250066320-A1 Active Ingredients with Sialagogue and Tingling/Fizzy Effect, and Preparations Containing Same TAS2R5, TAS2R7, TAS2R8 KDM4E 4202/4885ALDH1A1 2893/4885MEN1 714/4885
US-20230050965-A1 SSTR5 ANTAGONISTS SSTR5, GLP1R, GPR119 KDM4E 1415/4885ALDH1A1 2825/4885MEN1 2406/4885
US-20090203673-A1 4-HETEROCYCLOALKYLPYRI(MI)DINES, PROCESS FOR THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS CCNI, MKI67, CCNA1 KDM4E 783/4885ALDH1A1 293/4885MEN1 143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.